Ilyang Pharm Cash Flow Quality Index
Ilyang Pharm cash flow quality index. Ilyang Pharm (007570) has a Cash Flow Quality Index of 3.92x as of June 2025. Operating cash flow of ₩2.26 Billion exceeds net income of ₩576.52 Million, indicating high earnings quality where cash backs reported profits. Explore Ilyang Pharm debt service capacity to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Ilyang Pharm (2003–2024)
Cash flow quality index of Ilyang Pharm from 2003 to 2024. Historical Cash Flow Quality Index for Ilyang Pharm across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. See debt-free asset ratio of Ilyang Pharm to measure how much of total assets are equity-financed.
Ilyang Pharm Cash Flow Quality Index by Year (2003–2024)
Ilyang Pharm cash flow quality index by year from 2003 to 2024. Year-by-year earnings quality comparison for Ilyang Pharm. For the full cash flow conversion analysis, see cash flow conversion of Ilyang Pharm.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.55x | ₩5.61 Billion | ₩10.26 Billion | ▼ -52.7% |
| 2023 | 1.16x | ₩13.34 Billion | ₩11.52 Billion | ▼ -25.6% |
| 2022 | 1.56x | ₩29.94 Billion | ₩19.24 Billion | ▼ -66.6% |
| 2021 | 4.66x | ₩67.02 Billion | ₩14.38 Billion | ▼ -11.8% |
| 2020 | 5.28x | ₩57.48 Billion | ₩10.88 Billion | ▲ +45.8% |
| 2019 | 3.62x | ₩36.19 Billion | ₩9.98 Billion | ▼ -24.4% |
| 2017 | 4.79x | ₩30.03 Billion | ₩6.26 Billion | ▲ +4.9% |
| 2016 | 4.57x | ₩26.98 Billion | ₩5.91 Billion | ▼ -50.0% |
| 2015 | 9.13x | ₩40.27 Billion | ₩4.41 Billion | ▲ +1292.2% |
| 2013 | -0.77x | ₩-3.04 Billion | ₩3.96 Billion | ▼ -108.5% |
| 2003 | 9.01x | ₩10.08 Billion | ₩1.12 Billion | — |